PMC President: Changes Enhance Coalition's Ability to Promote Public Policies That Will Advance Personalized Medicine
WASHINGTON (January 10, 2018)
The Personalized Medicine Coalition (PMC) has added three leaders in personalized medicine from diverse backgrounds to its now 23-member Board of Directors and expanded its public policy capacity as part of an organizational restructuring. These changes, said PMC President Edward Abrahams, Ph.D., enhance the Coalition's ability to develop and promote public policies that will advance personalized medicine for the benefit of patients and the health system.
"Our diverse Board of Directors and new organizational structure put us in an excellent position to champion policies and practices that reflect consensus opinions and align with the personalized medicine principles underpinning many of the most promising opportunities in medicine," Abrahams said. "Doing so is essential to ensuring that every patient continues to get the best care possible."
Representing the pharmaceutical industry, community hospital systems and diagnostics companies, respectively, the new Board members include Anne-Marie Martin, Ph.D., Senior Vice President, Global Head of Precision Medicine, Novartis; Lincoln Nadauld, M.D., Ph.D., Executive Director, Precision Medicine, Precision Genomics, Intermountain Healthcare; and Werner Verbiest, Global Head, Janssen Diagnostics.
"As leaders in personalized medicine who are committed to PMC, each of these individuals has demonstrated a willingness to reach across sectors of the health system in order to advance the field, and will play a valuable role in steering PMC toward the field's most pressing issues in education and advocacy," said Board Chair Stephen L. Eck, M.D., Ph.D., President, CEO, Aravive Biologics.
As part of the restructuring, former director of operations Faswilla Sampson, M.S., will oversee the organization's strategic planning in education and advocacy as the Coalition's Vice President of Operations, and former director of communications Christopher J. Wells, M.P.A., will spearhead the Coalition's effort to increase awareness and understanding of personalized medicine in the U.S. and internationally as Vice President of Public Affairs.
David Davenport, now Manager of Public Policy & Secretary to the Board, will support PMC's expanding advocacy portfolio under the direction of Senior Vice President of Public Policy Cynthia A. Bens, who will continue to serve as the Coalition's primary liaison with the U.S. Congress and federal policymakers. Daryl Pritchard, Ph.D., will continue to lead PMC's science policy portfolio as Senior Vice President, Science Policy.
Former associate director of membership & development, Kayla Smith, will spearhead the continued expansion of the Coalition, which now includes more than 215 members, as Director of Membership & Development.
Board of Directors: Bios & Headshots
PMC Staff: Bios & Headshots
Christopher J. Wells
About the Personalized Medicine Coalition:
The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system. For more information about PMC, please visit www.personalizedmedicinecoalition.org.